Investig Clin Urol.  2019 Nov;60(6):442-446. 10.4111/icu.2019.60.6.442.

The association of family history of prostate cancer with the diagnosis of clinically significant prostate cancer in Korean population

• Park JS
• Koo KC
• Chung BH
• Lee KS

• KMID: 2461055
• DOI: http://doi.org/10.4111/icu.2019.60.6.442

Abstract

PURPOSE
The impact of family history on the diagnosis of the prostate cancer among Asian population remains controversial. We evaluated whether a positive family history of the prostate cancer in Korean men is associated with the diagnosis and aggressiveness of the prostate cancer.
MATERIALS AND METHODS
Patients who underwent a transrectal ultrasound-guided prostate biopsy from March 2015 to September 2017 were evaluated. Information on family history was obtained via a self-administered questionnaire. The presence of prostate cancer and clinically significant prostate cancer (Gleason score ≥7) was evaluated according to the presence of a family history.
RESULTS
Of 602 patients (median age, 68.3 years; median prostate-specific antigen level, 6.28 ng/mL), 41 (6.8%) patients had a family history of prostate cancer. Family history was a significant factor for detecting prostate cancer (odds ratio [OR], 2.99; 95% confidence interval [CI], 1.330-6.704; p=0.008). In multivariate analysis for predicting clinically significant prostate cancer, family history was a significant predictor (OR, 6.32; 95% CI; 2.790-14.298; p<0.001).
CONCLUSIONS
A family history of prostate cancer in Korean men was a significant factor for predicting prostate cancer. Moreover, significant differences in the aggressive features of the disease were identified between patients with and without a family history.

Keyword

Biopsy; History; Prostatic neoplasms

MeSH Terms

Asian Continental Ancestry Group
Biopsy
Diagnosis*
Humans
Male
Multiple Endocrine Neoplasia Type 1
Multivariate Analysis
Prostate*
Prostate-Specific Antigen
Prostatic Neoplasms*
Prostate-Specific Antigen

Reference

1. Carroll PH, Mohler JL. NCCN Guidelines updates: Prostate Cancer and Prostate Cancer Early detection. J Natl Compr Canc Netw. 2018; 16(5S):620–623. PMID: 29784740.

2. Lee DH, Lee SH, Rha KH, Choi IY, Lee JY, Kim SW, et al. The establishment of K-CaP (the multicenter Korean Prostate Cancer Database). Korean J Urol. 2013; 54:229–233. PMID: 23614058.

3. Li XG, Zhang DX, Cui XG, Xu DF, Hong Y, Li Y, et al. Evaluating the oncologic outcomes in 152 patients undergoing extraperitoneal laparoscopic radical prostatectomy. Chin Med J (Engl). 2012; 125:1529–1535. PMID: 22800816.

4. Egawa S, Suyama K, Arai Y, Tsukayama C, Matsumoto K, Kuwao S, et al. Treatment outcome by risk group after radical prostatectomy in Japanese men. Int J Urol. 2001; 8:295–300. PMID: 11389745.

5. Nagata Y, Sonoda T, Mori M, Miyanaga N, Okumura K, Goto K, et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J Nutr. 2007; 137:1974–1979. PMID: 17634273.

6. Bashir MN, Ahmad MR, Malik A. Risk factors of prostate cancer: a case-control study in Faisalabad, Pakistan. Asian Pac J Cancer Prev. 2014; 15:10237–10240. PMID: 25556453.

7. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17:1471–1474. PMID: 20180029.

8. Aprikian AG, Bazinet M, Plante M, Meshref A, Trudel C, Aronson S, et al. Family history and the risk of prostatic carcinoma in a high risk group of urological patients. J Urol. 1995; 154(2 Pt 1):404–406. PMID: 7541856.

9. Cussenot O, Valeri A, Meria P, Berthon P, Fournier G, Teillac P, et al. [Genetic aspects in cancers of the prostate]. Pathol Biol (Paris). 1996; 44:737–743. French. PMID: 8977935.

10. Gianferrari L, Arrigoni G, Cresseri A, Lovati G, Morganti G. [Genetic and clinico-statistical research on neoplasms of the prostate]. Acta Genet Med Gemellol (Roma). 1956; 5:224–233. Italian. PMID: 13326203.

11. Roemeling S, Roobol MJ, de Vries SH, Gosselaar C, van der Kwast TH, Schröder FH. Prevalence, treatment modalities and prognosis of familial prostate cancer in a screened population. J Urol. 2006; 175:1332–1336. PMID: 16515992.

12. Morrison BF, Aiken WD, Mayhew R, Gordon Y, Odedina FT. Prostate cancer knowledge, prevention, and screening behaviors in Jamaican men. J Cancer Educ. 2017; 32:352–356. PMID: 26842816.

13. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343:78–85. PMID: 10891514.

14. Johns LE, Houlston RS. A systematic review and meta-analysis of familial prostate cancer risk. BJU Int. 2003; 91:789–794. PMID: 12780833.

15. Bruner DW, Moore D, Parlanti A, Dorgan J, Engstrom P. Relative risk of prostate cancer for men with affected relatives: systematic review and meta-analysis. Int J Cancer. 2003; 107:797–803. PMID: 14566830.

16. Azzouzi AR, Valeri A, Cormier L, Fournier G, Mangin P, Cussenot O. Familial prostate cancer cases before and after radical prostatectomy do not show any aggressiveness compared with sporadic cases. Urology. 2003; 61:1193–1197. PMID: 12809896.

17. Raheem OA, Cohen SA, Parsons JK, Palazzi KL, Kane CJ. A family history of lethal prostate cancer and risk of aggressive prostate cancer in patients undergoing radical prostatectomy. Sci Rep. 2015; 5:10544. PMID: 26112134.

18. Saarimäki L, Tammela TL, Määttänen L, Taari K, Kujala PM, Raitanen J, et al. Family history in the Finnish Prostate Cancer Screening Trial. Int J Cancer. 2015; 136:2172–2177. PMID: 25274038.

19. Lee KS, Koo KC, Chung BH. The impact of a family history of prostate cancer on the prognosis and features of the disease in Korea: results from a cross-sectional longitudinal pilot study. Int Urol Nephrol. 2017; 49:2119–2125. PMID: 28905176.